|Enzon Pharmaceuticals & Santaris||SPC2968||Oncology||Hypoxia Inducible Factor 1 alpha (HIF-1 alpha) antagonist - tagetting angiogenesis, cell proliferation, apoptosis, cell invasion|
|Celsus Laboratorie||Intimatan||Anti- coagulent: For example, to prevent blood clots during cardiac surgery (replacing heparin)||heparin cofactor II agonist|
|CoGenesys||Neugranin||decrease infection in patients receiving myelo- suppressive anti-cancer drugs||long-acting form of Granulocyte Colony Stimulating Factor (G-CSF)|
|BN Immuno- Therapeutics||MVA-BN(R)-HER2||Oncology - breast cancer vaccine||Induce multi-pronged immunity as well as anti-tumor activity|
|Medivir||MV-701||osteoporosis, osteoarthritis, rheumatoid arthritis, Paget's disease and certain tumours causing bone metastases||Cathepsin K inhibitor|
The first in a new series of periodic roundups of drugs that have moved from preclinical research into clinical testing via the announcement of a Phase I trial or an application for a trial to industry regulators.